Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population
Johansson, Per LU
; Mattsson, Niklas
; Hansson, Oskar
LU
; Wallin, Anders
; Johansson, Jan-Ove
; Andreasson, Ulf
; Zetterberg, Henrik
; Blennow, Kaj
LU
and Svensson, Johan
(2011)
In Journal of Alzheimer's Disease
24(3).
p.537-546
- Abstract
- The cerebrospinal fluid (CSF) biomarkers amyloid-beta (A beta)(1-42), T-tau, and P-tau have good diagnostic accuracy for clinically diagnosed Alzheimer's disease (AD). However, in multi-center studies, the predictive values of the CSF biomarkers have been lower, possibly due to differences in procedures for lumbar puncture and CSF handling and storage, and to differences in patient populations, clinical evaluations, and diagnostic procedures. Here we investigate the diagnostic accuracy of CSF biomarkers in a well defined homogeneous mono-center population. We also evaluate an extended panel of amyloid related biomarkers. Sixty consecutive patients admitted for cognitive impairment to a memory clinic were recruited. The participants... (More)
- The cerebrospinal fluid (CSF) biomarkers amyloid-beta (A beta)(1-42), T-tau, and P-tau have good diagnostic accuracy for clinically diagnosed Alzheimer's disease (AD). However, in multi-center studies, the predictive values of the CSF biomarkers have been lower, possibly due to differences in procedures for lumbar puncture and CSF handling and storage, and to differences in patient populations, clinical evaluations, and diagnostic procedures. Here we investigate the diagnostic accuracy of CSF biomarkers in a well defined homogeneous mono-center population. We also evaluate an extended panel of amyloid related biomarkers. Sixty consecutive patients admitted for cognitive impairment to a memory clinic were recruited. The participants included patients with AD or mild cognitive impairment (MCI) diagnosed with AD upon follow-up (n = 32), patients with stable MCI (n = 13), patients with other dementias diagnosed at primary evaluation or upon follow-up (n = 15), and healthy controls (n = 20). CSF was analyzed for A beta(1-42), T-tau, P-tau, A beta(X-38), A beta(X-40), A beta(X-42), sA beta PP alpha, and sA beta PP beta. In multivariate analysis, the core biomarkers A beta(1-42), T-tau, and P-tau demonstrated a high ability to diagnose AD versus the combined groups of controls and stable MCI, with an area under the receiver operating characteristic curve (AUROC) of 0.97 (95% CI 0.93-1.00, p < 0.0001). The additional biomarkers only marginally increased AUROC to 0.98 (95% CI 0.95-1.00, p < 0.0001), this increase mainly mediated by A beta(X-42). In conclusion, CSF biomarkers A beta(1-42), T-tau, and P-tau have very high diagnostic accuracy in a well defined cohort of untreated patients, demonstrating the excellent potency of CSF biomarkers to identify pathological processes in AD when a stringent analytical protocol is used. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2094124
- author
- Johansson, Per
LU
; Mattsson, Niklas
; Hansson, Oskar
LU
; Wallin, Anders
; Johansson, Jan-Ove
; Andreasson, Ulf
; Zetterberg, Henrik
; Blennow, Kaj
LU
and Svensson, Johan
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, amyloid, biomarkers, cerebrospinal fluid, diagnosis
- in
- Journal of Alzheimer's Disease
- volume
- 24
- issue
- 3
- pages
- 537 - 546
- publisher
- SAGE Publications
- external identifiers
-
- wos:000292496900011
- scopus:79957854917
- pmid:21297262
- ISSN
- 1387-2877
- DOI
- 10.3233/JAD-2011-101878
- project
- Endocrine and diagnostic aspects of cognitive impairment
- language
- English
- LU publication?
- yes
- id
- 13a306a4-9503-4136-bb01-a7eb4a6b1de7 (old id 2094124)
- date added to LUP
- 2016-04-01 10:16:27
- date last changed
- 2025-04-04 15:13:43
@article{13a306a4-9503-4136-bb01-a7eb4a6b1de7,
abstract = {{The cerebrospinal fluid (CSF) biomarkers amyloid-beta (A beta)(1-42), T-tau, and P-tau have good diagnostic accuracy for clinically diagnosed Alzheimer's disease (AD). However, in multi-center studies, the predictive values of the CSF biomarkers have been lower, possibly due to differences in procedures for lumbar puncture and CSF handling and storage, and to differences in patient populations, clinical evaluations, and diagnostic procedures. Here we investigate the diagnostic accuracy of CSF biomarkers in a well defined homogeneous mono-center population. We also evaluate an extended panel of amyloid related biomarkers. Sixty consecutive patients admitted for cognitive impairment to a memory clinic were recruited. The participants included patients with AD or mild cognitive impairment (MCI) diagnosed with AD upon follow-up (n = 32), patients with stable MCI (n = 13), patients with other dementias diagnosed at primary evaluation or upon follow-up (n = 15), and healthy controls (n = 20). CSF was analyzed for A beta(1-42), T-tau, P-tau, A beta(X-38), A beta(X-40), A beta(X-42), sA beta PP alpha, and sA beta PP beta. In multivariate analysis, the core biomarkers A beta(1-42), T-tau, and P-tau demonstrated a high ability to diagnose AD versus the combined groups of controls and stable MCI, with an area under the receiver operating characteristic curve (AUROC) of 0.97 (95% CI 0.93-1.00, p < 0.0001). The additional biomarkers only marginally increased AUROC to 0.98 (95% CI 0.95-1.00, p < 0.0001), this increase mainly mediated by A beta(X-42). In conclusion, CSF biomarkers A beta(1-42), T-tau, and P-tau have very high diagnostic accuracy in a well defined cohort of untreated patients, demonstrating the excellent potency of CSF biomarkers to identify pathological processes in AD when a stringent analytical protocol is used.}},
author = {{Johansson, Per and Mattsson, Niklas and Hansson, Oskar and Wallin, Anders and Johansson, Jan-Ove and Andreasson, Ulf and Zetterberg, Henrik and Blennow, Kaj and Svensson, Johan}},
issn = {{1387-2877}},
keywords = {{Alzheimer's disease; amyloid; biomarkers; cerebrospinal fluid; diagnosis}},
language = {{eng}},
number = {{3}},
pages = {{537--546}},
publisher = {{SAGE Publications}},
series = {{Journal of Alzheimer's Disease}},
title = {{Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population}},
url = {{http://dx.doi.org/10.3233/JAD-2011-101878}},
doi = {{10.3233/JAD-2011-101878}},
volume = {{24}},
year = {{2011}},
}